Skip to main content

Table 8 Annual costs in Norwegian krone (Norway)

From: Real-world costs of autosomal dominant polycystic kidney disease in the Nordics

Costs in NOK, mean (95% CI)

CKD 1–3 (n = 64)

CKD 4–5 (n = 55)

Dialysis (n = 61)

Transplant (n = 63)

P value

Direct costs

38,676 (18,712–69,343)

80,145 (51,159–118,538)

851,277 (765,334–959,286)

185,108 (131,915–251,557)

<0.0001

Hospitalisations

12,898 (4387–28,610)

33,291 (13,098–66,704)

138,766 (93,249–195,108)

65,036 (32,637–109,347)

<0.0001

Outpatient care visits

4425 (3355–5859)

8085 (6588–10,612)

12,050 (8956–15,673)

12,840 (10,094–16,706)

<0.0001

Primary care visits

691 (345–1224)

1205 (246–3192)

507 (145–1594)

351 (140–772)

.5094

Surgical procedures

4209 (89–15,018)

23,660 (10,359–40,439)

106,888 (67,415–153,360)

6798 (1790–14,265)

<0.0001

Diagnostic tests

1652 (1100–2273)

1959 (1417–2622)

6423 (5132–8002)

3359 (2450–4587)

<0.0001

Home care/medical assistance

12,317 (48–36,245)

885 (66–2396)

14,151 (5074–27,170)

3090 (359–9872)

.0002

Routine dialysis care

495,052 (468,607–518,867)

16,131 (4245–32,431)

<0.0001

Haemodialysis transportation

32,460 (25,631–39,573)

128 (0–256)

<0.0001

Drug use

2483 (1472–3707)

11,060 (8445–14,068)

44,980 (39,925–51,304)

77,375 (64,093–95,936)

<0.0001

 Antihypertensives

530 (435–640)

715 (621–808)

522 (433–617)

567 (461–687)

.02459

 Phosphate binders

1158 (565–1850)

8072 (6345–9932)

418 (102–944)

<0.0001

 ESAs

36 (0–148)

2036 (778–3600)

14,079 (11,772–16,055)

2086 (827–3610)

<0.0001

 Analgesics for kidney pain

16 (6–31)

103 (33–251)

104 (29–256)

33 (3–98)

.1053

 Vitamin D analogues

1833 (857–3090)

6360 (4761–8104)

12,170 (11,121–12,991)

4200 (2861–5722)

<0.0001

 Immunosupressants

2741 (290–6569)

69,324 (56,582–87,711)

<0.0001

 Other drugs

68 (19–164)

688 (181–1422)

7292 (5804–8788)

746 (353–1326)

<0.0001

Indirect costs

111,441 (70,268–157,539)

204,324 (143,043–268,451)

215,588 (144,283–280,047)

182,164 (125,099–242,812)

.0604

Productivity loss

110,892 (70,085–157,480)

199,644 (139,793–263,028)

197,961 (129,783–259,106)

180,251 (123,425–241,038)

.2452

Informal care

548 (0–1645)

4680 (1603–9442)

17,627 (7001–35,752)

1913 (761–3473)

<0.0001

Total costs

150,117 (104,759–202,958)

284,469 (206,680–373,107)

1,066,865 (950,458–1,204,094)

367,272 (278,949–466,269)

<0.0001

  1. P values calculated with Kruskal–Wallis test
  2. NOK Norwegian krone, ESA erythropoiesis-stimulating agent, CI confidence interval (bias corrected)